We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

104 hedge funds and large institutions have $287M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 18 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more capital invested

Capital invested by funds: $98.2M → $287M (+$189M)

133% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 18

110% more call options, than puts

Call options by funds: $1.42M | Put options by funds: $676K

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

6% more funds holding

Funds holding: 98 → 104 (+6)

Holders
104
Holders Change
+6
Holders Change %
+6.12%
% of All Funds
1.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
42
Reduced
18
Closed
18
Calls
$1.42M
Puts
$676K
Net Calls
+$746K
Net Calls Change
+$444K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$16.9M
2
PBA
Paradigm Biocapital Advisors
New York
+$10.1M
3
Fisher Asset Management
Fisher Asset Management
Washington
+$7.16M
4
Millennium Management
Millennium Management
New York
+$5.08M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.95M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$17.4M
2
CA
CHI Advisors
New York
-$5.06M
3
Renaissance Technologies
Renaissance Technologies
New York
-$4.13M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$3.47M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
CWM
51
Curi Wealth Management
North Carolina
$734K -$297K -26,000 -31%
UBS Group
52
UBS Group
Switzerland
$700K +$637K +55,770 +26,183%
Wells Fargo
53
Wells Fargo
California
$680K +$258K +22,606 +71%
RJFSA
54
Raymond James Financial Services Advisors
Florida
$649K +$1.37K +120 +0.2%
Squarepoint
55
Squarepoint
New York
$602K +$311K +27,255 +130%
T. Rowe Price Associates
56
T. Rowe Price Associates
Maryland
$597K – – –
PP
57
PDT Partners
New York
$570K -$388K -33,932 -43%
S
58
SignatureFD
Georgia
$558K +$1.94K +170 +0.4%
AWM
59
AE Wealth Management
Kansas
$550K +$503K +44,005 New
ADIM
60
Alpha DNA Investment Management
Maryland
$530K +$485K +42,477 New
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$530K +$460K +40,264 +1,888%
BC
62
Birchview Capital
Vermont
$500K – – –
JF
63
Jump Financial
Illinois
$493K -$17.8K -1,554 -4%
SG Americas Securities
64
SG Americas Securities
New York
$479K +$2.37K +207 +0.5%
BWA
65
BDO Wealth Advisors
Florida
$440K – – –
VF
66
Virtu Financial
New York
$436K +$284K +24,842 +246%
Two Sigma Advisers
67
Two Sigma Advisers
New York
$330K -$64K -5,600 -18%
EGM
68
Engineers Gate Manager
New York
$329K +$53.4K +4,674 +22%
CNBT
69
Cornerstone National Bank & Trust
Illinois
$312K – – –
MFG
70
Magnus Financial Group
New York
$312K +$286K +25,000 New
BC
71
BIT Capital
Germany
$290K +$265K +23,199 New
FSA
72
Franklin Street Advisors
North Carolina
$289K – – –
Bank of New York Mellon
73
Bank of New York Mellon
New York
$243K +$44.2K +3,872 +25%
Simplex Trading
74
Simplex Trading
Illinois
$243K +$223K +19,501 New
SFI
75
Susquehanna Fundamental Investments
Pennsylvania
$226K +$207K +18,100 New
1 2
3
4 5

GTHX Hedge Fund Activity: Q3 2022 in Review

104 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2022, worth a combined $287M — up 193% from $98.2M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new GTHX positions and 18 closed out — a net gain of 7 holders — while 42 added to existing stakes and 18 trimmed.

The largest buyer was State Street, adding an estimated $16.9M. The largest seller was Woodline Partners, cutting an estimated $17.4M.

  • 104 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2022, up from 98 in Q2 2022.
  • Funds reported $287M of G1 Therapeutics, Inc. Common Stock stock for Q3 2022, up 193% quarter-over-quarter.
  • 25 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2022 and 18 closed out, a net change of +7 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2022 was State Street, an estimated $16.9M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2022 was Woodline Partners, an estimated $17.4M sold.

Based on aggregated 13F filings for Q3 2022.